Quotient, a U.K. focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
It is months since the chatter around Chinese sequencing giant BGI's initial public offering advanced from "will it happen?" to "when, where and how much?" Now Bloomberg has some answers. A $400 million IPO in Hong Kong is reportedly penciled in for the fourth quarter.
European financial markets have largely missed out on the biotech IPO boom, with the few local companies to go public traveling to the U.S. to file their papers. Now British vaccine developer Circassia is to test investor appetite in the United Kingdom with a bumper $285 million IPO.
The past year will go down as the biggest for biotech IPOs since 2000 and a good time for the firms who braved frosty conditions to go public in 2011 and 2012. Vaccine developer Genocea Biosciences is now set to be among the first to test conditions in 2014 having filed its S-1 just before the holiday season.
Inogen has unveiled plans for an IPO worth as much as $86.2 million, becoming one of the few medical device companies to make such a move this year.
Oxford Immunotec Global's Nasdaq debut is relatively modest, though initial trading appeared to boost the price. The developer of a tuberculosis blood test priced its initial shares below range, a sign that the fall surge of diagnostics and medical device IPOs may have peaked.
CardioDx was among the cluster of diagnostics and med tech companies that joined a march to the public markets earlier this fall. But executives have now decided to delay the company's IPO, according to various media reports, citing poor market conditions.
Biocept Laboratories released some details of its IPO plan, and the California cancer diagnostic maker's turn at the public markets remains a modest one.
AutoGenomics has officially pulled back from a proposed IPO filed more than a year ago, adding a downbeat note to an otherwise promising fall during which some diagnostics companies are jumping full-on into the public markets.